SA
DGX icon

Seneschal Advisors’s Quest Diagnostics DGX Stock Holding History

Seneschal Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$588 Buy
3
+1
+50% +$194 ﹤0.01% 330
2025
Q4 		$348 Hold
2
– – ﹤0.01% 451
2025
Q3 		$382 Buy
+2
New +$355 ﹤0.01% 433

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Seneschal Advisors's DGX Position: Q1 2026 in Review

Seneschal Advisors increased its Quest Diagnostics (DGX) stake by 50% in Q1 2026, buying an estimated $194 and bringing the position to 3 shares worth $588. The position accounts for ﹤0.01% of the portfolio, ranked #330.

Seneschal Advisors first reported a position in DGX in Q3 2025 and has held it in 3 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Seneschal Advisors held 3 shares of Quest Diagnostics worth $588 as of Q1 2026.
  • Seneschal Advisors bought 1 Quest Diagnostics share in Q1 2026, an estimated $194.
  • Quest Diagnostics made up ﹤0.01% of Seneschal Advisors's portfolio in Q1 2026, its #330 holding.
  • Seneschal Advisors first reported a position in Quest Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Seneschal Advisors's 13F filing for Q1 2026, filed 8 May 2026.